Teva- Pharmaceutical Industries Ltd
NYSE: TEVA
$17.51
-$0.25 (-1.4%)
Closing Price on September 20, 2024
TEVA Articles
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Published:
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is trying to transform itself by making its generics business even larger if it can pull off its desire to acquire Mylan N.V. (NASDAQ: MYL)....
Published:
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Published:
Back in November of 2010, 24/7 Wall St. first issued a list of stocks to own for the next decade. Even long-term investors need to assess their portfolios from time to time.
Published:
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
ThinkstockThe trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics can enter the market. Now the...
Published:
Wednesday's top analyst upgrades, downgrades and initiations include Altera, Amazon.com, Chipotle Mexican Grill, Halliburton, MGIC Investment, Nokia, SAP and Teva Pharmaceutical.
Published:
Teva Pharmaceutical Industries has just approached Mylan with a public takeover bid valued at $82 per share in cash and stock.
Published:
Tuesday's top analyst upgrades and downgrades include Brocade Communications, IAC/InterActiveCorp, Nabors Industries, Priceline, Teva Pharmaceutical and Yamana Gold.
Published:
News broke Monday that Teva Pharmaceutical Industries will acquire Auspex Pharmaceuticals. Existing investors will be wondering if they are getting enough in this buyout.
Published:
Prior to the markets opening Thursday, Teva Pharmaceutical reported its most recent financial results.
Published:
24/7 Wall St. has put together a preview of some of the larger companies reporting quarterly results in the coming week.
Published:
Teva Pharmaceutical announced on Monday that the FDA approved the first generic equivalent to Nexium delayed-release capsules in the United States.
Published:
A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.
Published:
Friday's top analyst upgrades, downgrades and initiations include Citrix Systems, GoPro, Hewlett-Packard, Microsoft, Oracle and Teva Pharmaceutical.
Published: